LB PHARMACEUTICALS INC

LB Pharmaceuticals Inc

Equities

LBRX

US50180M1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-11 pm EDT			5-day change	1st Jan Change
24.68 ^USD	+2.75%		+1.15%	+10.87%

Mar. 09	Certain Class A Common Stock Warrants of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	Certain Series B Common Stock Warrants of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI

LB Pharmaceuticals Inc(NasdaqGM:LBRX) added to Russell 3000E Index

Published on 12/18/2025

S&P Capital IQ

LB PHARMACEUTICALS INC

+2.75%

-0.11%

LB Pharmaceuticals Inc(NasdaqGM:LBRX) added to Russell 3000E Index

© S&P Capital IQ - 2025

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	LB PHARMACEUTICALS INC	24.68USD	+2.75%	+1.15%	624M
	RUSSELL 3000	3,849.98PTS	-0.11%	-1.56%	-

Latest news about LB Pharmaceuticals Inc

Mar. 09	Certain Class A Common Stock Warrants of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	Certain Series B Common Stock Warrants of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	Certain Series B-1 Common Stock Warrants of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	Certain Stock Options of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	3,433,470 Common Stock of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	Certain Warrant of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026.	CI
Mar. 09	LB Pharmaceuticals Inc Appoints Robert Lenz, M.D., Ph.D. to Board of Directors	CI
Feb. 05	LB Pharmaceuticals announces $100.0 million private placement	RE
Feb. 05	LB Pharmaceuticals Plans $100 Million Private Placement	MT
Feb. 03	LB Pharmaceuticals Inc announced that it expects to receive $100.000121 million in funding from Commodore Capital, Balyasny Asset Management L.P,Caligan Partners, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners, and other investors	CI
Jan. 26	LB Pharmaceuticals Inc. Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program	CI
Jan. 26	LB Pharmaceuticals Initiates Phase 2 Trial of LB-102 to Treat Bipolar Depression	MT
Jan. 21	LB Pharmaceuticals Inc Appoints Minako Pazdera as General Counsel	CI
Jan. 09	Roth Capital Initiates Coverage on LB Pharmaceuticals With Buy Rating	MT
Jan. 06	LB Pharmaceuticals, Inc Announces Appointment of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture	CI

Chart LB Pharmaceuticals Inc

Duration

Period

Chart LB Pharmaceuticals Inc

LBRX: Dynamic Chart

Company Profile

Employees

16

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

4

Last Close Price

24.68USD

Average target price

44.50USD

Spread / Average Target

+80.31%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stock Market News
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000E Index

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!

BENEFIT NOW